Live feed10:00:00·751dPRReleasevia QuantisnowNanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 TherapyByQuantisnow·Wall Street's wire, on your screen.NBTX· Nanobiotix S.A.Health Care
